An interventional study of A manualised post-traumatic growth intervention for people with hematological cancers in Blood Cancers, Leukemia and Lymphoma, sponsored by University of West Attica. Active, not recruiting at 2 sites in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by University of West Attica · Not applicable, Interventional, and Supportive care
This clinical trial aims to determine whether a manualised group intervention for people with blood cancers can help them experience positive psychological changes following their diagnosis, known as post-traumatic growth. Participants receiving the intervention will be compared with those receiving usual care and placed on a waiting list. Participants will be randomly allocated to either the group intervention or the usual care/waiting-list group. The study will also explore how this intervention could be implemented within the Greek healthcare system. The study aims to answer the following main questions: (1) Does this psychological group intervention increase post-traumatic growth in people with blood cancers? (2) Does this intervention improve other outcomes, including anxiety, depression, quality of life, psychological well-being, cognitive functioning, distress, illness understanding and routine blood markers? Participants will: (1) Attend nine weekly face-to-face group sessions in Greek, each lasting approximately two hours, with other people living with blood cancers. (2) Receive a detailed manual/workbook covering the session content and be encouraged to use it between sessions. (3) Have the opportunity to participate in an optional outdoor activity of their choice. (4) Complete questionnaires and a brief cognitive assessment before and after the intervention, together with other assessments as required. Participation is voluntary and free of charge. Some participants may experience mild emotional discomfort when discussing their experiences; however, psychological support will be available if needed. The findings will help researchers determine whether this group intervention can support people living with blood cancers and inform the future implementation of similar interventions within the Greek healthcare system.
Hematological cancers and their treatments can significantly affect the body, social interactions, and psychological health of individuals who experience them. However, such traumatic experiences provide individuals with the opportunity to change and experience what is known as post-traumatic growth. Post-traumatic growth is defined as the positive psychological changes that happen after a traumatic life crisis, and in people with cancer has been connected to biopsychosocial variables like quality of life and biomarkers.
The objectives of this non-pharmacological randomized controlled trial with pre-post measures are implemented in two phases. Phase 1 - Post-traumatic growth intervention: (1) Develop a post-traumatic growth intervention manual, (2) Investigate the feasibility of implementing a post-traumatic growth intervention in the Greek healthcare system, (3) Assess the effectiveness of a psychological intervention in increasing post-traumatic growth and other biopsychosocial variables in people with hematological cancers. Phase 2 - Policy recommendations for the Greek healthcare system: (1) Develop best practice guide on the psychosocial support of people with hematological malignancies in Greece, (2) Develop health policy recommendations on the integration of psychosocial interventions in oncological health care in Greece.
In this context, a systematic review and meta-analysis of the literature on the findings of interventions in the post-traumatic development of people with cancer was conducted and published (https://doi.org/10.1002/pon.6241). The conclusions of the meta-analysis (e.g., components, methods) contributed to the development of an intervention manual (that features education, self-reflection, behavioral activation, connecting and sharing with others, processing and coping with trauma, emotional regulation techniques, and an introduction to mindfulness meditation).
Following this, a pilot study (n = 6) was conducted to assess the feasibility and acceptability of the manual in this setting. Participants also shared their views and experiences of the intervention.
What follows is a randomized controlled trial, recruiting from major hospitals and patient societies. Measurements include questionnaires (e.g., quality of life, anxiety, depression) and biomarkers (CRP, hemoglobin, albumin).
Participants in the experimental group (expected n = 40) will participate in 9 weekly group meetings lasting 120 minutes each, for 6-10 people. Participants in the control group will receive usual care without any intervention (expected n = 40), but will be offered the intervention after the main study is completed. Participants will be assessed at baseline and at follow-up intervals, using self-reported questionnaires, a brief cognitive assessment (namely the Montreal Cognitive Assessment) and biomarkers.
This is one of the first randomized controlled trials in post-traumatic growth for people with hematologic cancers and is expected to contribute to the available evidence-based interventions for people with hematologic cancers through publications in peer-reviewed journals.
1,444 studies on the registry are indexed under Hematologic Neoplasms; 420 are open to participants now.
This study's planned enrollment of 80 is above the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.
Browse Hematologic Neoplasms studies →University of West Attica is the lead sponsor of 31 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Control group, waiting list, usual care
Interventional arm during which participants join a weekly peer group
Behavioral: A manualised post-traumatic growth intervention for people with hematological cancers
The intervention consists of nine weekly two-hour group sessions and an optional outdoor activity, delivered over a total period of approximately 2.5 months. Participants will also be encouraged to engage in 30 minutes of daily practice (e.g., reading, writing) related to the intervention content and manual/workbook. The core components of the intervention are summarized by the acronym TRANSFORM: Teach, Reflect, Activate Behavior, Network \& Connect, Share, Face \& Cope, Open up \& Write up, Regulate Emotions, Meditate \& Mindfulness. These elements are designed to enhance participants' skills to understand cancer and manage related thoughts, emotions, and behaviors. The intervention is grounded in PTG theory and prior empirical evidence.
Also known as: TRANSFORM: Teach, Reflect, Activate Behaviour, Network & Connect, Share, Face & Cope, Open up & Write up, Regulate Emotions, Meditate & Mindfulness, TRANSFORM: Teach, Reflect, Activate Behavior, Network & Connect, Share, Face & Cope, Open up & Write up, Regulate Emotions, Meditate & Mindfulness
Posttraumatic Growth Inventory - X (PTGI-X)
PTGI-X is a validated, 25-item, theory-driven questionnaire scored on a 6-point Likert scale, with scores ranging from 0-125, where higher scores indicate higher PTG.
Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.
Impact of Event Scale - Revised (IES-R)
The IES-R is a validated 22-item measure of subjective distress of an individual's response to a specific traumatic event. IES-R measures the impact of the trauma over the last 7 days using a 5-item Likert scale. Scores range from 0-99, with higher scores indicating higher impact.
Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.
Brief Illness Perceptions Questionnaire (BIPQ)
BIPQ is composed of eight closed questions rated on a 10-point Likert scale, and one open question. The items tap into categories of illness perceptions and how participants understand elements around their illness. Reverse scoring is needed in some questions. Scores range from 0-80, with higher scores indicating worse illness perceptions.
Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.
Hospital Anxiety and Depression Scale (HADS)
HADS is a 14-item scale, using a 4-point Likert scale which can be used to measure anxiety and depression, with a higher score indicating higher mental health difficulties. Scores range from 0-21 for each subscale and 0-42 for the total.
Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.
Functional Assessment of Chronic Illness Therapy-Spiritual Well-being (FACIT-Sp)
FACIT-Sp is a 12-item measure of QoL and well-being that uses 5-point Likert scales. Accounting for reverse scoring, scores range from 0-48, with higher scores indicating better QoL and well-being.
Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.
Montreal Cognitive Assessment (MoCA)
MoCA is an administered cognitive assessment sensitive to mild cognitive changes. Scores range from 0-30, with higher scores indicating better cognitive function.
Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.
Functional Assessment of Cancer Therapy - Leukemia (FACT-Leu)
FACT-Leu is a 44-item quality of life disease-specific measure. Accounting for reverse scoring, scores range from 0-176 with higher scores indicating better quality of life.
Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.
Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym)
FACT-Lym is a 42-item quality of life disease-specific measure. Accounting for reverse scoring, scores range from 0-168, with higher scores indicating better quality of life.
Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.
Functional Assessment of Cancer Therapy - Bone Marrow Transplantation (FACT-BMT)
FACT-BMT is a 50-item quality of life disease-specific measure, scoring between 0-200. Accounting for reverse scoring, higher scores indicate better quality of life.
Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.
Biomarkers
(1) Hemoglobin is a protein in red blood cells that transports oxygen or carbon dioxide from the lungs to tissues and back. (2) C-reactive protein (CRP) is a protein produced in response to inflammation which is a sensitive but non-specific marker of acute inflammation, infection, or tissue injury. (3) Albumin is a plasma protein, synthesized by the liver, maintaining oncotic pressure and transporting hormones, drugs, and ions.
Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — All sensitive information will be stored according to the EU General Data Protection Regulation (GDPR). The researcher will have access to the data and will allow others (e.g., supervisors) to access this data if they have a legitimate reason to do so. No one outside the research team will have access to the data.
Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.
Of 185 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's planned 30 months is below that.
Counting every sponsor, half of 191 studies reached it within 40 months; a quarter within 21 and three quarters within 125.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of West Attica